Market Size
The global Crohn’s disease market is estimated to reach USD 14.6 billion in 2025 and is expected to reach USD 21.8 billion by 2033, growing at a CAGR of 6.5% during the forecast period 2026 to 2033. The market is witnessing steady growth driven by the increasing prevalence of inflammatory bowel diseases and rising awareness about early diagnosis and treatment options.
Crohn's disease is one of the inflammatory bowel diseases (IBD) which is marked by an illness in the intestines. It presents itself with symptoms like stomach ache, extreme bowel movement, tiredness, loss of appetite which leads to weight loss and malnourishment. There are the inflammation which is majorly in a part of the intestines that are also complicated by deeper layers of the bowel. This disease can be very painful, disabling, and sometimes, even deadly as it may attack different parts of the digestive system.
Market Summary
| Metrics | Details |
| CAGR | 6.5% |
| Market Size Available for Years | 2022-2031 |
| Estimation Forecast Period | 2024-2031 |
| Revenue Units | Value (US$ Mn) |
| Segments Covered | Type |
| Drug Class | |
| Route of Administration | |
| Distribution Channel | |
| Regions Covered | North America, Europe, Asia-Pacific, South America, and Middle East & Africa |
For more details on this report – Request for Sample
Market Dynamics: Drivers & Restraints
The Crohn’s Disease Market is witnessing steady growth driven by the increasing prevalence of inflammatory bowel diseases and rising awareness about early diagnosis and long-term disease management. Crohn’s disease, a chronic gastrointestinal condition, requires continuous treatment, which is boosting demand for advanced therapeutics such as biologics, immunomodulators, and targeted therapies. The growing adoption of monoclonal antibodies and biosimilars is significantly improving patient outcomes by reducing inflammation and maintaining remission. Additionally, advancements in diagnostic techniques, increasing healthcare expenditure, and expanding research in personalized medicine are further supporting market expansion.
However, the market faces several challenges that could restrain its growth. High treatment costs, particularly for biologics and long-term therapies, can limit accessibility for patients in developing regions. Variability in patient response, potential side effects, and the risk of disease relapse remain key concerns in treatment effectiveness. Moreover, stringent regulatory requirements and the complexity of clinical trials for gastrointestinal diseases can delay product approvals. Despite these challenges, ongoing innovation in targeted therapies, increasing focus on early intervention, and the development of novel drug delivery systems are expected to create strong growth opportunities in the global Crohn’s disease market.
Market Segment Analysis
The global crohn’s disease market is segmented based on type, drug class, route of administration, distribution channel and region.
Drug Class:
Anti-inflammatory Drugs segment is expected to dominate the market share
The anti-inflammatory drugs segment are expected to hold a significant portion of the market share. Medication therapy is very important in controlling symptoms of Crohn's disease, particularly in this case, the anti-inflammatory medication which aims at reducing inflammation within the gastrointestinal tract so as to relieve the symptoms and also avert active disease more so flare-ups.
These drugs which include aminosalicylates (e.g., mesalamine) and corticosteroids (prednisone) are common at the initiation of the disease or in mild to moderate exacerbations. Aminosalicylates help reduce the inflammation at the mucosal layer of the intestines.
The use of corticosteroids also has a significant beneficial effect in inducing remission than placebo and other agents such as 5-aminosalicylic acids (5-ASA) , Treatment of most studies indicates that they can help reach remission rates almost twice those of placebo treatments1. More so, they are at their maximal efficiency when used for a long period (more than 15 weeks), and for most patients, will resolve symptoms in a matter of days.
Aminosalicylates, a first-line treatment for UC, contain the ingredient 5-aminosalicylic acid (5-ASA). These drugs, including mesalamine, olsalazine, balsalazide, and sulfasalazine, help reduce inflammation in the intestine and are best for mild to moderate UC. The American Gastroenterological Association (AGA) recommends adults with mild to moderate UC take a standard dose of oral mesalamine, olsalazine, or balsalazide instead of low dose mesalamine or sulfasalazine or no treatment.
Biologics segment is the fastest-growing segment in the crohn’s disease market share
Biologics have significantly improved the global Crohn's disease treatment by offering targeted, effective options for managing moderate to severe cases. These therapies, including TNF inhibitors, integrin inhibitors, and IL blockers, modulate the immune system to reduce inflammation and prevent disease flare-ups. They are especially beneficial for patients who do not respond well to conventional treatments, as they maintain remission and reduce the need for corticosteroids. Their efficacy in minimizing gut damage, enhancing quality of life, and potentially reducing hospitalization rates has led to their increased adoption and development.
For instance, in October 2024, Johnson & Johnson released data showcasing TREMFYA (guselkumab), in Crohn’s disease (CD) and ulcerative colitis (UC) with high rates of endoscopic remission in both biologic-naive and biologic-refractory patients (including UC patients who are JAK-inhibitor refractory), meaning the intestinal mucosa appeared uninflammed.
Route of Administration:
Injectable segment is expected to dominate the crohn’s disease market share
Injectable route of administration are of utmost importance especially in cases where moderate to severe therapies are required. Injectable biologics, which include therapies such as adalimumab, a TNF inhibitor, are generally given via the subcutaneous or intravenous routes and help regulate inflammation. These treatment modalities are indicated for patients who have experienced a poor response to standard oral therapies, since these intravenous drugs rapidly resolve symptoms and help to attain and sustain remission. The injectable form of the treatment ensures excellent bioavailability, thereby making it possible to taper disease symptoms and progression to the level where hospitalization would not be needed.
The oral segment is the fastest-growing segment in the Crohn’s disease market share
Oral therapy is an important component in the treatment of Crohn's disease at both the initial and maintenance stages for mild to moderate cases. They include aminosalicylates, corticosteroids, and immunomodulators, which help reduce inflammation and prevent flares from occurring in patients with mild disease. Oral formulations have the advantage of a non-invasive mode of administration, thereby promoting patient compliance as the drugs do not require clinical visits. With recent advancements, newer oral therapies, including small-molecule inhibitors, are emerging, which provide targeted action with fewer adverse reactions than conventional medications.
For instance, in May 2023, a new treatment option for moderate-to-severe Crohn's disease patients has been approved by the Food and Drug Administration. The once-daily oral medication, upadacitinib, suppresses intestinal inflammation and painful symptoms, helping patients achieve and maintain clinical and endoscopic remission. The study was published in The New England Journal of Medicine.
Market Geographical Share
North America is expected to hold a significant position in the Crohn’s Disease market share
North America is expected to hold a significant position in the global Crohn’s Disease market during the forecast period due to the novel drug launches, FDA approvals, ongoing clinical trials, high prevalence of crohn’s disease cases in the region and other factors help the region to grow during the forecast period.
For instance, in June 2024, AbbVie declared that the Food and Drug Administration (FDA) in the United States has approved SKYRIZI (risankizumab-rzaa) for adults suffering from moderate to severe ulcerative colitis and moderate to severe Crohn's disease. It is anticipated that this launch strategy will assist the organization in diversifying its range of products.
Moreover, in October 2023, Eli Lilly and Company has announced that in VIVID-1, a Phase 3 study investigating the safety and efficacy of mirikizumab for adult patients with moderately to severely active Crohn’s disease, an investigational interleukin-23p19 antagonist protocolled as mirikizumab has succeeded in meeting the co-primary and all centrala secondary endpoints as compared to placebo. The double-blind, treat-through trial included mirikizumab, placebo and active control (ustekinumab) arms.
Asia-Pacific is growing at the fastest pace in the crohn’s disease market
Asia-Pacific holds the fastest pace in the crohn’s disease market and is expected to hold most of the market share due to increasing prevalence of inflammatory bowel diseases and increased awareness. Moreover, partnerships, agreements, westernized lifestyles, high in processed foods and lower in fiber, have led to a rise in gastrointestinal disorders, including Crohn's disease. Improved healthcare infrastructure and access to advanced diagnostic tools have led to earlier diagnoses and increased demand for effective treatments.
For instance, in August 2024, Biocon Biologics has signed a settlement and license agreement with Janssen Biotech Inc., Janssen Sciences Ireland, and Johnson & Johnson to resolve patent disputes and commercialize its biosimilar, Bmab 1200, in Europe, the UK, Canada, and Japan. The settlement secures market entry dates in these regions, and Biocon's regulatory filings are currently under review. Bmab 1200 is a proposed biosimilar to Janssen's Stelara, used for treating conditions like psoriasis, Crohn's disease, and psoriatic arthritis.
Recent Developments
February 2026: Across North America, Europe, and Asia Pacific, rising prevalence of Crohn’s disease and increasing adoption of advanced biologics significantly accelerated demand for targeted inflammatory bowel disease (IBD) therapies. Recent approvals of next-generation biologics further expanded treatment access and improved disease control outcomes.
January 2026: Globally, advancements in IL-23 inhibitors, JAK inhibitors, and anti-integrin therapies improved long-term remission rates, reduced relapse frequency, and strengthened personalized treatment approaches for moderate-to-severe Crohn’s disease.
December 2025: Leading companies such as AbbVie Inc., Johnson & Johnson, Takeda Pharmaceutical Company Limited, Pfizer Inc., and UCB S.A. strengthened their IBD portfolios by advancing TNF inhibitors, IL-23 blockers, and oral small-molecule therapies, focusing on higher efficacy and improved patient convenience.
November 2025: Increasing adoption of biologics and biosimilars improved treatment accessibility and affordability, while combination therapies enhanced remission induction in refractory Crohn’s cases.
October 2025: Companies intensified investments in oral targeted therapies, microbiome-based treatments, and precision medicine approaches, aiming to overcome biologic resistance and reduce long-term disease progression risks.
September 2025: Across key regions including the United States, Germany, China, Japan, and India, rising healthcare expenditure, improved diagnostic rates, and expanding access to biologics significantly supported market growth.
The Crohn’s disease market is rapidly shifting toward biologic-first treatment strategies, supported by IL-23 inhibitors and next-generation oral therapies, transforming long-term disease management and patient quality of life.
Market Companies
The major global players in the market include Biogen, Merck & Co, Novartis AG, Janssen Biotech, Inc, Takeda Pharmaceuticals, UCB S.A, AbbVie, Prometheus Laboratories among others.
Why Purchase the Report?
- To visualize the global crohn’s disease market segmentation based on type, drug class, route of administration, distribution channel, and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development.
- Excel data sheet with numerous data points of crohn’s disease market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as Excel consisting of key products of all the major players.
The global crohn’s disease market report would provide approximately 70 tables, 69 figures, and 202 pages.
Target Audience 2026
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
